Immuneering Stock Rises on Positive Phase 2a Data

Immuneering shares are trading higher after Mizuho raised its price target on the stock to $10 from $8, maintaining an Outperform rating, following positive updated Phase 2a data for its lead asset IMM-1-104 in first-line pancreatic cancer.